Product Name:  Retatrutide Freeze-dried Powder (Retatrutide Lyophilized Powder)
CAS Number: 2381089-83-2
Molecular Formula: C221H342N46O68
Molecular Weight: 4730.91
Purity: >99.00%
Dosages: 5mg/vial, 10mg/vial, 15mg/vial, 20mg/vial, 30mg/vial or customized.

Brief Introduction:
Retatrutide is an active compound launched by Eli Lilly in June 2023. It is a triple (GLP-1/GIP/Gcg) agonist based on the GLP/GI dual receptor agonist tirzepatide through a hybrid glucagon-like (GlucagonGcg) structure and is a drug for the treatment of obesity and type 2 diabetes. This active compound can activate receptor agonists in our body, which helps control blood sugar levels and manage weight loss.

Sequence:
H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA )-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Mechanism of action:
Retatrutide achieves comprehensive metabolic regulation through triple receptor activation:
※ GLP-1R: Slows gastric emptying, enhances satiety, and reduces appetite.
※ GIPR: Regulates hunger signals in the central nervous system, further suppresses appetite, and improves energy metabolism.

※ GCGR: Promotes glucagon secretion, accelerates fat and glycogenolysis, and increases basal metabolism.

Indications and efficacy:
★ Treatment of obesity:
In a phase II clinical trial, patients in the highest dose group (12 mg) lost an average of 24.2% of their body weight after 48 weeks, with some patients losing more than 30%.

★ Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD):
Retatrutide can reduce liver fat content by 86%, and more than 85% of patients achieved regression of hepatic steatosis.

★ Type 7 diabetes:
Significantly reduces glycated hemoglobin (HbA1c) and improves blood sugar control.

★ Potential cardiovascular benefits:
Animal studies have shown that it may indirectly protect cardiovascular health by improving blood pressure and heart function, but further clinical confirmation is needed.

Market Prospects and Challenges:
◎ Differentiation Advantages:
Compared with existing GLP-1 single-target (e.g., semaglutide) or dual-target (e.g., tirzepatide) drugs, the triple mechanism of retatrutide holds greater potential in terms of weight loss and metabolic improvement.
◎ Cost and Availability:
Currently, the production cost of peptide drugs is relatively high, but the long-acting properties of retatrutide may reduce the frequency of medication administration and improve patient compliance.